1)Wang C, et al:A novel coronavirus outbreak of global health concern. Lancet 395(10223) : 470-473, 2020. PMID 31986257
2)Gorbalenya AE, et al:Coronaviridae Study Group of the International Committee on Taxonomy of Viruses : The species Severe acute respiratory syndrome-related coronavirus ; classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 5(4) : 536-544, 2020. PMID 32123347
3)Wang CC, et al : Airborne transmission of respiratory viruses. Science 373(6558) : eabd9149, 2021. PMID 34446582
4)Oran DP, et al : Prevalence of asymptomatic SARS-CoV-2 infection ; a narrative review. Ann Intern Med 173(5) : 362-367, 2020. PMID 32491919
5)Johansson MA, et al : SARS-CoV-2 transmission from people without COVID-19 symptoms. JAMA Netw Open 4(1) : e2035057, 2021. PMID 33410879
6)Williamson EJ, et al : Factors associated with COVID-19-related death using OpenSAFELY. Nature 584(7821) : 430-436, 2020. PMID 32640463
7)Lauer SA, et al : The incubation period of coronavirus disease 2019(COVID-19)from publicly reported confirmed cases ; estimation and application. Ann Intern Med 172(9) : 577-582, 2020. PMID 32150748
8)Giacomelli A, et al : Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection; a cross-sectional study. Clin Infect Dis 71(15) : 889-890, 2020. PMID 32215618
9)Huang C, et al : Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223) : 497-506, 2020. PMID 31986264
10)Lu R, et al : Genomic characterisation and epidemiology of 2019 novel coronavirus ; implications for virus origins and receptor binding. Lancet 395(10224) : 565-574, 2020. PMID 32007145
11)Cao W, et al : COVID-19 ; towards understanding of pathogenesis. Cell Res 30(5) : 367-369, 2020. PMID 32346073
12)Polak SB, et al : A systematic review of pathological findings in COVID-19 ; a pathophysiological timeline and possible mechanisms of disease progression. Mod Pathol 33(11) : 2128-2138, 2020. PMID 32572155
13)Tang N, et al : Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18(4) : 844-847, 2020. PMID 32073213
14)Gattinoni L, et al : COVID-19 pneumonia ; different respiratory treatments for different phenotypes? Intensive Care Med 46(6) : 1099-1102, 2020. PMID 32291463
15)Dhont S, et al : The pathophysiology of ‘happy' hypoxemia in COVID-19. Respir Res 21(1) : 198, 2020. PMID 32723327
16)Qin C, et al : Dysregulation of immune response in patients with coronavirus 2019(COVID-19) in Wuhan, China. Clin Infect Dis 71(15) : 762-768, 2020. PMID 32161940
17)Xu Z, et al : Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8(4) : 420-422, 2020. PMID 32085846
18)Siddiqi HK, et al : COVID-19 illness in native and immunosuppressed states ; a clinical-therapeutic staging proposal. J Heart Lung Transplant 39(5) : 405-407, 2020. PMID 32362390
19)診療の手引き検討委員会:新型コロナウイルス感染症(COVID-19)診療の手引き 第6.0版.厚生労働省,2021. https://www.mhlw.go.jp/content/000851077.pdf
20)U.S.National Institutes of Health : Coronavirus Disease 2019(COVID-19)Treatment Guidelines. 2021. https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf
21)Fadel R, et al : Early short-course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis 71(16) : 2114-2120, 2020. PMID 32427279
22)Ranjbar K, et al : Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients ; a triple-blinded randomized controlled trial. BMC Infect Dis 21(1) : 337, 2021. PMID 33838657
23)Edalatifard M, et al : Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients ; results from a randomised controlled clinical trial. Eur Respir J 56(6) : 2002808, 2020. PMID 32943404
24)Marconi VC, et al : Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19(COV-BARRIER) ; a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med S2213-2600(21) : 00331-00333, 2021. PMID 34480861
25)Nalbandian A, et al : Post-acute COVID-19 syndrome. Nat Med 27(4) : 601-615, 2021. PMID 33753937
26)Carvalho-Schneider C, et al : Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect 27(2) : 258-263, 2021. PMID 33031948
27)Carfì A, et al : Persistent symptoms in patients after acute COVID-19. JAMA 324(6) : 603-605, 2020. PMID 32644129
28)Nasserie T, et al : Assessment of the frequency and variety of persistent symptoms among patients with COVID-19 ; a systematic review. JAMA Netw Open 4(5) : e2111417, 2021. PMID 34037731
29)Huang C, et al : 6-month consequences of COVID-19 in patients discharged from hospital ; a cohort study. Lancet 397(10270) : 220-232, 2021. PMID 33428867
30)Nehme M, et al : Prevalence of symptoms more than seven months after diagnosis of symptomatic COVID-19 in an outpatient setting. Ann Intern Med 174(9) : 1252-1260, 2021. PMID 34224254
31)Taquet M, et al : Incidence, co-occurrence, and evolution of long-COVID features ; a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med 18(9) : e1003773, 2021. PMID 34582441
32)Greenhalgh T, et al : Management of post-acute covid-19 in primary care. BMJ 370 : m3026, 2020. PMID 32784198
33)Myall KJ, et al : Persistent post-COVID-19 interstitial lung disease. An observational study of corticosteroid treatment. Ann Am Thorac Soc 18(5) : 799-806, 2021. PMID 33433263
34)Liu K, et al : Respiratory rehabilitation in elderly patients with COVID-19 ; a randomized controlled study. Complement Ther Clin Pract 39 : 101166, 2020. PMID 32379637
35)診療の手引き 別冊 罹患後症状のマネジメント編集委員会:新型コロナウイルス感染症(COVID-19)診療の手引き 別冊 罹患後症状のマネジメント 暫定版.厚生労働省,2021. https://www.mhlw.go.jp/content/000860932.pdf